Few new drugs deserve expedited regulatory treatment.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33908278.
- Also identified by DOI 10.18553/jmcp.2021.27.5.685 and PMC identifier 10390900.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> This commentary is based on work by the author that was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. The funders had no role in the writing of this commentary, or the decision to submit for publication. The author has nothing else to disclose.
Medical subject headings
- Drug Approval
- Government Regulation